Screener
Kailera Therapeutics KLRA Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Kailera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The source filing: Kailera Therapeutics’s 10-Q, filed May 26, 2026.
- Filed
- May 26, 2026, 4:29 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-239417
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total operating expenses | 84,660 | 20,458 |
| Loss from operations | (84,660) | (20,458) |
| Other income | ||
| Interest income | 5,716 | 1,675 |
| Other income, net | 79 | 800 |
| Total other income | 5,795 | 2,475 |
| Net loss | $(78,865) | $(17,983) |
| Other comprehensive loss |
Item 1. Financial Statements.
FAQ
- What is Kailera Therapeutics's interest expense?
- Kailera Therapeutics (KLRA) reported interest expense of $5.72M in Q1 2026.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about Kailera Therapeutics's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude